Pierre Debs Managing Partner & Founder, DrD GmbH AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering to unlock the potential of phytocannabinoids in designing medical therapies.   ESCHBORN, Germany, Oct 25th, 2021 – Innoplexus, a global leader in AI-based drug discovery and development; and DrD, an innovative biotechnology company focused on phytocannabinoids, are partnering to accelerate the clinical development and market authorization of novel medications based on phytocannabinoids and other phytochemicals, leveraging Innoplexus’ leading AI technology.   ..read more

https://innoplexus-marketing.s3.amazonaws.com/video/Parexel+Teaser+vParexel.mp4   Michelle Hoiseth, Chief Data Officer for Parexel and Dr. Gunjan Bhardwaj, CEO Innoplexus discuss the importance of access to the latest COVID-19 data. The new COVID-19 Clearinghouse developed in partnership renders hundreds of thousands of coronavirus-related content searchable for users, updated in real-time and accessible for free. The post Partnering to make 100,000s COVID-19 publications searchable appeared first on Innoplexus ..read more

The cost of developing a new drug roughly doubles every nine years (inflation-adjusted) aka Eroom’s law.     As the volume of data for drug discovery and development explodes, the ability of Pharma and medical practitioners to keep up and accelerate drug discovery becomes more challenging. In contrast, the software industry reaps the benefits of Moore’s law with high powered computing, and increased internet bandwidth.   How can Pharma transition from Eroom’s law to Moore’s law and beyond?   A transition to Moore’s Law can only be achieved by the joint effect of technolog ..read more

In medicine, a Biomarker is a biological indicator, which can mark a state of a biology and is measurable. A Biomarker or a combination of few biomarkers can establish the biological state of an individual helping us understand the exact disease state and potential treatments. As a simple example, biomarker for fever is high temperature.   Biomarker discovery is important because there are many diseases in which biomarkers are still not identified. A perfect example of this is the ongoing pandemic, where COVID-19 is impacting different age groups differently. Not only that, reports of di ..read more

The post Accelerate Biomarker Discovery with AI appeared first on Innoplexus ..read more

AI technologies are more widely used in the pharmaceutical industry today to enable for its extensive review of scientific and medical literature. Extensive data obtained through AI can support the discovery of potential biomarkers, accelerate drug development and identify repurposing opportunities.1 The FDA sees tremendous potential in technologies such as machine and deep learning in healthcare.   Keen interest in using automated technologies is rapidly expanding across the pharmaceutical and biotechnology industries. The FDA, has been developing a new regulatory framework to promote i ..read more

The World Health Organization announced a pandemic in April 2020. Artificial intelligence technologies have presented effective methods for accelerating research, monitoring spread of infection and to identify effective treatments to fight with the novel coronavirus. Here are the various ways in which artificial intelligence has proved to be effective during this pandemic.   I. Monitoring the Pandemic:   A. Epidemiological patterns: AI tools can help in mining of news and online information to provide early warnings. AI prediction can help project the number of cases likely to occur ..read more

First discovered in December 2019 in China, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had spread worldwide. By April 2020 it was declared a pandemic by the World Health Organization (WHO). There is now a race to developing a vaccine to cure COVID-19 (coronavirus disease 2019).   COVID-19, which has affected more than 7 Million people across the world by June 2020, is not only highly contagious but also deadly. Therefore, finding a cure for this disease is the foremost priority for the pharmaceutical and biotechnology industry. Can this be done without the help of a ..read more

The pharmaceutical industry is facing a pivotal time in the evolution of clinical research and trials. Emerging technologies with unprecedented potential are improving trial efficiency, safety, and accuracy. Improved methods of data collection and handling are at the forefront of these developments, leading to better procedures and enhanced outcomes.   Real-time data makes a huge difference. The large volume of scientific and medical data today is doubling at a faster rate than ever before, so analyzing this data in real-time is crucial to gaining knowledge and deriving value. The better ..read more

Traditional drug discovery measures stand at the forefront of change with the developments that the pharmaceutical industry’s collaboration with technology has brought in. Several challenges in data collection, handling, and sharing are improved processes through new tools that focus on accelerating the drug development cycle with accurate, almost real-time data.   The drug development process includes many steps and challenges. These include challenges such as discovering unmet needs, designing optimal trials, keeping informed about competitors, as well as the regular reviewing of treat ..read more